Clinical Trial Search

Primary: Proteinuria — 2.4; 1.6; 1.2; 1.6 g/24hr

Primary: Fold Change in Pretomanid AUC(0-last) in Participants With Renal Impairment as Compared to Matched Healthy Controls — 77130; 63600; 62660 ng*h/mL

Primary: Geometric Least Squares Mean Area Under the Plasma Drug Concentration-time Curve From Time Zero to Infinity (AUC0-∞) Following a Single IV Dose of Sugammadex — 339; 151…

Primary: Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) — 259; 293 nanogram per milliliter (ng/mL)

Primary: Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine — 53.9; 54.6 µM*hr

Primary: Area Under the Plasma Concentration Time Curve (AUC) From Hour 0 to Infinity (AUC[0-inf]) of Gepotidacin for Part 1 — 14838; 22367; 28545 Nanogram*hour per milliliter

Primary: Renal Oxygenation — 22.4; 22.5 s^-1

Primary: Changes in Renal Blood Flow — 9590.8; 5105.4; 8529.4; 5228.4 h.mL/min

Primary: Serum 25-hydroxyvitamin D — 26.7; 22.4 ng/mL — p=0.003

Primary: Percentage of Participants Achieving Sustained Viral Response 12 Weeks After Completing Study Therapy (SVR12) — 90.0; 100.0 Percentage of participants

Primary: Change in Insulin Resistance After 12 Weeks of Vitamin D3 Supplementation — 0.01; -0.27 HOMA score — p=0.95

Primary: Percentage of Participants With Response — 0; 15; 65; 10 percentage of participants

Primary: Maximum Observed Plasma Concentration (Cmax) of PF-07321332 — 1600; 2077; 2210; 2369 Nanogram per milliliter

Primary: Percent Change in Fractional Excretion of Sodium (FENA) — 41; -5.0 percentage of change — p==0.012

Primary: [Parts 1 and 2] Mean Area Under the Concentration-Time Curve From Time Zero Up to Infinity (AUC0-inf) of Gefapixant 50 mg (Categorical Analysis) — 6450; 9970; 9990; 8590…